Honasa Consumer fell 3.48% to Rs. 405.20 today, despite the company announcing its entry into the high-growth nutraceuticals space through the acquisition of a 58% stake in Fluence Pharma for Rs. 135 crore. The stock opened higher at Rs. 432.85, close to its 52-week high of Rs. 437.90, but slipped to an intraday low of Rs. 402.35, suggesting that investors used the acquisition-led rally to book profits.

Trigger

• Honasa will acquire 58% stake in Fluence Pharma for Rs. 135 crore.
• Fluence Pharma is a science-backed nutraceuticals company with patented Cyclical Nutrition Therapy and dermatologist-led distribution.
• Honasa will acquire the remaining 42% stake in two tranches over the next 5 to 7 years.
• The move marks Honasa’s entry into the Rs. 16,000 crore-plus nutraceuticals market through a new subsidiary, Honasa Health.

The stock is falling because the market appears unconvinced about the near-term earnings payoff from the acquisition. While nutraceuticals is a high-growth category and fits Honasa’s “inside-out beauty” strategy, investors are likely questioning whether this is an immediate value-accretive move or a long-gestation diversification outside the company’s core beauty and personal care business.

There is also a capital-allocation concern. At Rs. 135 crore for a 58% stake, with the balance 42% to be acquired over the next 5 to 7 years, the deal creates future payout obligations. Unless Honasa gives clear details on Fluence’s revenue, profitability, margins and growth trajectory, the market may find it difficult to assess whether the acquisition price is attractive.